Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

Phase 2

Terminated

• Conditions: Metastatic Colorectal Cancer
• Interventions: Drug: Trifluridine/Tipiracil then Regorafenib; Drug: Regorafenib then Trifluridine/Tipiracil

• Registration Number: NCT04450836
• Lead Sponsor: UNICANCER

Brief Summary

A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer

Detailed Description

Multicenter, international, comparative, randomized, open-label, phase II study conducted in two parallel groups.

The study population will consist of male and female patients aged ≥18 years old with metastatic colorectal cancer after failure of fluoropyrimidine-, irinotecan-, and oxaliplatin-based chemotherapies, as well as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors in patients eligible for these treatments.

Patients will be randomized according to a 1:1 ratio to treatment arms A and B.

* Arm A: regorafenib until disease progression or unacceptable toxicity occurs, followed by trifluridine/tipiracil until disease progression or unacceptable toxicity occurs.

* Arm B: trifluridine/tipiracil until disease progression or unacceptable toxicity occurs, followed by regorafenib until disease progression or unacceptable toxicity occurs.

Study Timeline

• Study First Submitted: 2020-06-24
• Study First Submitted QC: 2020-06-24
• Study First Posted: 2020-06-30
• Study Start: 2020-11-23
• Primary Completion: 2024-03-23
• Study Completion: 2024-12-31
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-25
• Last Update Posted: 2025-03-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 234

Inclusion Criteria

1. Patients must have provided informed consent before performing any study specific procedures.

2. Histological or cytological documented adenocarcinoma of the colon or rectum.

3. Patients with metastatic colorectal cancer (stage IV).

4. Measurable disease, defined as at least one unidimensional measurable lesion on a computed tomography (CT) scan according to RECIST v1.1.

5. The patient must have progressed following exposure of all the following agents : one fluoropyrimidine-based chemotherapy (capecitabine or fluorouracil [5-FU], combined with oxaliplatin and/or irinotecan (including FOLFOX, FOLFIRI or FOLFOXIRI) as well as EGFR and/or VEGF inhibitors in patients eligible for these treatments.

6. Patients considered eligible for treatment with both regorafenib and trifluridine-tipiracil.

7. Male or female patients aged ≥18 years.

8. ECOG performance status of ≤1.

9. Adequate bone marrow, liver and renal functions as assessed by the following laboratory requirements:

   • Total bilirubin ≤1.5 x upper limit of normal (ULN).
   • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 x ULN for patients with liver metastasis).
   • Alkaline phosphatase limit ≤2.5 x ULN (≤5 x ULN for patients with liver metastasis).
   • Serum creatinine ≤1.5 x ULN.
   • International normalized ratio (INR) and partial thromboplastin time (PTT) ≤1.5 x ULN. Patients receiving anticoagulants, such as warfarin or heparin are eligible if there is no prior evidence of an underlying abnormality with coagulation.
   • Platelet count ≥75000 /mm³, hemoglobin (Hb) ≥9 g/dL, absolute neutrophil count (ANC) ≥1500/mm³. Blood transfusions to meet this inclusion criterion are not allowed.

10. Women of childbearing potential and men must agree to use a highly effective contraception (1% failure rate) from the signing of the informed consent form until at least 6 months after the last study drug administration. Women using hormonal contraceptive must also use a barrier method.

11. Women of childbearing potential must have a negative pregnancy test within 7 days before starting study treatment.

12. Patients affiliated to the social security system.

13. Patient willing and able to comply with the protocol for the duration of the study including treatment, scheduled visits, and examinations throughout the study, including follow up.

Exclusion Criteria

1. Patients with symptomatic brain or meningeal metastasis, unless definitive therapy occurred more than 6 months ago and with a confirmation of tumoral control within 4 weeks of starting study treatment.

2. Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to study inclusion, except for curatively treated in situ cervical cancer, non-melanoma skin cancer, and superficial bladder tumors: staged Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor with lamina propria invasion).

3. Prior treatment with regorafenib or any other tyrosine kinase inhibitor.

4. Prior treatment with trifluridine/tipiracil.

5. Known hypersensitivity to any of the study drugs, study drug classes, or study drug excipients.

6. Unresolved toxicity grade >1 (by CTCAE v5.0) caused by prior therapy/procedure, excluding alopecia, hypothyroidism, and oxaliplatin-induced neurotoxicity grade ≤2.

7. Patient with moderate or severe hepatic impairment (Child-Pugh C).

8. Known UGT1A1 polymorphisms. History of Gilbert's syndrome.

9. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before starting study treatment.

10. Chemotherapy within 21 days of starting study treatment.

11. Radiotherapy within 4 weeks of starting study treatment, except for palliative radiotherapy within 2 weeks.

12. Active cardiac disease including any of the Following:

    • Congestive heart Failure: New York Heart Association (NYHA) class ≥2.
    • Unstable angina (angina symptoms at rest), or a new-onset angina (within the 3 months before enrolment).
    • Myocardial infarction that occurred less than 6 months before enrolment.
    • Cardiac arrhythmias requiring anti-arrhythmic therapy (treatment with beta blockers or digoxin are permitted)
    • Uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic pressure >90 mmHg despite treatment).

13. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months of starting study treatment.

14. Ongoing infection grade 2 (CTCAE v5.0).

15. Known history of human immunodeficiency virus (HIV) infection.

16. Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy.

17. Patients with seizure disorder requiring medication.

18. Patients with a history of any bleeding diathesis, irrespective of the severity.

19. Any hemorrhage or bleeding event grade ≥3 (CTCAE v5.0) within 4 weeks before starting study treatment.

20. Presence of a wound, ulcer, or bone fracture that is not healing.

21. Patients unable to swallow oral medications.

22. Bowel malabsorption or extended bowel resection that could affect the absorption of regorafenib, occlusive syndrome.

23. Presence of gastro-intestinal fistula or perforation.

24. Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and their compliance in the study.

25. Patients participating in another therapeutic study within the 30 days before enrolment.

26. Pregnant or breast feeding women.

27. Person deprived of their liberty or under protective custody or guardianship.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm B (TT-R)	Trifluridine/Tipiracil then Regorafenib	Trifluridine-tipiracil followed by Regorafenib.
Arm A (R-TT)	Regorafenib then Trifluridine/Tipiracil	Regorafenib followed by trifluridine-tipiracil.

Primary Outcome Measures

Name	Time	Method
To evaluate the feasibility of treatment sequence (R-TT or TT-R)	Expected duration of 5 months from randomization	The feasibility of the treatment sequence is defined as the percentage of subjects able to receive both regorafenib and trifluridine/tipiracil according to the sequence in 3rd and 4th line. Subjects will be considered as having received both 3rd and 4th lines if they are administered at least two cycles of each line of therapy, i.e. percentage of patients being treated until the first tumor evaluation.

Secondary Outcome Measures

Name	Time	Method
To evaluate the efficacy of treatment sequence (R-TT or TT-R) in terms of Overall Survival rate	Expected duration of 9 months from randomization	Overall Survival (OS) is defined as the time interval from randomization until death from any cause.
To evaluate the safety (Treatment-Emergent Adverse Events) during treatment	Expected 30 days after last study treatment administration, up to 5 years	Data concerning adverse events graded using the common terminology criteria for adverse events (CTCAE) v5.0 will be collected during the study.
To evaluate the efficacy of treatment sequence (R-TT or TT-R) in terms of the Objective response rate (ORR)	Expected duration of 6 months from randomization	Objective response rate (ORR) is defined as percentage of patients with a best response being either complete response \[CR\] or partial response \[PR\] during treatment. ORR will be assessed in each study arm.
To evaluate the efficacy of treatment sequence (R-TT or TT-R) in terms of the Disease control rate (DCR)	Expected duration of 6 months from randomization	Disease control rate (DCR) is defined as percentage of patients with a best response that is not progressive disease (PD) (either complete response \[CR\], partial response \[PR\], or stable disease \[SD\]) during treatment. DCR will be assessed in each study arm.
To evaluate the efficacy of treatment sequence (R-TT or TT-R) in terms of the Time-to-treatment failure 1 (TTF1)	Expected duration of 3 months from randomization	Time-to-treatment failure 1 (TTF1) is defined as the time from randomization to treatment discontinuation for any reason (including disease progression, treatment toxicity, patient preference, or death) during the first sequence of treatment in each arm.
To evaluate the efficacy of treatment sequence (R-TT or TT-R) in terms of the Time-to-treatment failure 2 (TTF2)	Expected duration of 6 months from randomization	Time-to-treatment failure 2 (TTF2) is defined as the time from randomization to treatment discontinuation for any reason (including disease progression, treatment toxicity, patient preference, or death) during the second sequence of treatment in each arm.
To evaluate the efficacy of treatment sequence (R-TT or TT-R) in terms of the Progression-free survival 2 (PFS2)	Expected duration of 6 months from randomization	Progression-free survival 2 (PFS2) is defined as the time interval from randomization until death or the disease progression is observed in the later sequence of treatment in each arm, evaluated using RECIST v1.1.
To evaluate the health-related quality of life of cancer patients during treatment	Expected 30 days after last study treatment administration, up to 5 years	Quality of life data using the patient reported outcomes, quality of life questionnaire - Core 30 (QLQ-C30) version 3.0 will be collected during the study.; Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.; The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.; All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
To evaluate the efficacy of treatment sequence (R-TT or TT-R) in terms of the progression-free Survival 1 (PFS1)	Expected duration of 3 months from randomization	Progression-free survival 1 (PFS1) is defined as the time interval from randomization until death or the disease progression observed in the first sequence of treatment in each arm, evaluated using Response evaluation criteria in solid tumors (RECIST) v1.1.
To evaluate the performance status deterioration	Expected 30 days after last study treatment administration, up to 5 years	The time to Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2 deterioration is defined as the time interval between randomization and the first documented ECOG PS ≥2 during the study.

Trial Locations

Locations (36)

Centre hospitalier d'Auxerre; 🇫🇷 Auxerre, France

Infirmerie Protestante de Lyon; 🇫🇷 Caluire-et-Cuire, France

Centre Antoine Lacassagne; 🇫🇷 Nice, France

CHU de Bordeaux - Hôpital Haut Lévèque; 🇫🇷 Pessac, France

CHU de Poitiers; 🇫🇷 Poitiers, France

Association Hôpital Saint Joseph de Marseille; 🇫🇷 Marseille, France

CH Saint Jean; 🇫🇷 Perpignan, France

Hôpital Privé des Côtes d'Armor - Centre CARIO-HPCA; 🇫🇷 Plérin, France

Hôpital Privé Pays de Savoie; 🇫🇷 Annemasse, France

Hôpital Scorff; 🇫🇷 Lorient, France

Centre Hospitalier de Saint Malo; 🇫🇷 Saint-Malo, France

Institut de Cancérologie de Lorraine; 🇫🇷 Vandoeuvre Les Nancy, France

Hôpital Privé des Peupliers; 🇫🇷 Paris, France

Clinique Saint Luc; 🇧🇪 Bouge, Belgium

CH Périgueux; 🇫🇷 Perigueux, France

Groupe hospitalier Pitié Salpétrière; 🇫🇷 Paris, France

Centre Léon Bérard; 🇫🇷 Lyon, France

Centre Paul Strauss (ICANS); 🇫🇷 Strasbourg, France

Centre Hospitalier de Valence; 🇫🇷 Valence, France

Paul Brousse; 🇫🇷 Villejuif, France

Institut Sainte Catherine; 🇫🇷 Avignon, France

Centre Hospitalier de Bayeux; 🇫🇷 Bayeux, France

Centre François Baclesse; 🇫🇷 Caen, France

CH Cotentin; 🇫🇷 Cherbourg, France

Institut de Cancérologie de Bourgogne; 🇫🇷 Dijon, France

Centre Oscar Lambret; 🇫🇷 Lille, France

Hôpital privé du Confluent; 🇫🇷 Nantes, France

APHP - Hôpital Européen Georges Pompidou; 🇫🇷 Paris, France

Hopital Charles Nicolle; 🇫🇷 Rouen, France

CHU Hôpital Nord; 🇫🇷 Saint-Étienne, France

CHU de Toulouse; 🇫🇷 Toulouse, France

CHU - Robert Debre; 🇫🇷 Reims, France

Institut Jean Godinot; 🇫🇷 Reims, France

Gustave Roussy; 🇫🇷 Villejuif, France

CH Verviers; 🇧🇪 Verviers, Belgium

CH de l'Ardenne; 🇧🇪 Libramont, Belgium